Renal cell carcinoma (RCC) is a common urologic tumor with a poor prognosis. Cannabinoid receptor 1 (CB1), which is a G protein-coupled receptor, has recently been reported to participate in the genesis and development of various cancers. However, the exact role of CB1 in RCC is unknown. The aim of this study was to determine the role of CB1 in RCC cell lines and RCC prognosis, thus underlying its potential as a therapeutic target. Immunohistochemistry and western blots were performed to investigate the expression of CB1 in RCC tissues and to determine its clinicopathological significance in RCC patients. Additionally, we explored CB1 expression in RCC cell lines and evaluated the effect of AM251, a CB1 inverse agonist, and in vitro siRNA knockdown of CB1 on the cellular proliferation, migration, and apoptosis of RCC cell lines. CB1 was overexpressed in cancerous tissues compared with adjacent normal tissues. Furthermore, CB1 expression levels were an independent risk factor for overall survival for RCC patients. AM251 significantly decreased tumor cell proliferation and induced cell apoptosis by upregulating the expression of the pro-apoptotic protein Bax and decreasing the expression of the anti-apoptotic proteins survivin and Bcl-2. Migration of the RCC cell lines was also significantly inhibited after treatment with AM251 compared with untreated control groups. In addition, knockdown of CB1 expression significantly decreased cell proliferation and invasion and significantly increased apoptosis of RCC cells. CB1 expression is functionally associated to cellular proliferation, apoptosis, and invasion ability of RCC. Our data suggest that CB1 might be a potential target for RCC clinical therapy.
This is a preview of subscription content, access via your institution.
Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21. doi:10.1016/j.eururo.2011.06.049.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016. doi:10.3322/caac.21338.
Acar O, Sanli O. Surgical Management of local recurrences of renal cell carcinoma. Surgery research and practice. 2016;2016:2394942. doi:10.1155/2016/2394942.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24. doi:10.1016/j.eururo.2015.01.005.
Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016. doi:10.1007/s00345-016-1773-y.
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012;23(4):973–80. doi:10.1093/annonc/mdr362.
Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anti-Cancer Drugs. 2016;27(5):383–97. doi:10.1097/cad.0000000000000335.
Lainez N, Garcia-Donas J, Esteban E, Puente J, Saez MI, Gallardo E, et al. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study BMC cancer. 2016;16(1):135. doi:10.1186/s12885-016-2084-9.
Le Saux O, Freyer G, Negrier S. First-line treatments for poor-prognosis metastatic renal cell carcinoma: experts’ prescribing practices and systematic literature review. Clinical drug investigation. 2016;36(5):389–99. doi:10.1007/s40261-016-0384-0.
Mechoulam R. Recent advantages in cannabinoid research. Forschende Komplementarmedizin. 1999;6(Suppl 3):16–20.
Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, et al. Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. Oncol Rep. 2010;23(1):171–5.
Ciaglia E, Torelli G, Pisanti S, Picardi P, D’Alessandro A, Laezza C, et al. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients’ cells. Oncotarget. 2015;6(17):15464–81. doi:10.18632/oncotarget.3895.
Mukhopadhyay B, Schuebel K, Mukhopadhyay P, Cinar R, Godlewski G, Xiong K, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology (Baltimore, Md). 2015;61(5):1615–26. doi:10.1002/hep.27686.
Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. European journal of cancer (Oxford, England: 1990). 2009;45(1):174–82. doi:10.1016/j.ejca.2008.10.010.
Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171(1):31–8. doi:10.1016/j.cancergencyto.2006.06.014.
O’Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014;27:126–35. doi:10.1016/j.ceb.2014.01.005.
Nikan M, Nabavi SM, Manayi A. Ligands for cannabinoid receptors, promising anticancer agents. Life Sci. 2016;146:124–30. doi:10.1016/j.lfs.2015.12.053.
Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets. 2011;15(3):297–308. doi:10.1517/14728222.2011.553606.
Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P, et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer. 2008;122(4):742–50. doi:10.1002/ijc.23114.
Gustafsson K, Wang X, Severa D, Eriksson M, Kimby E, Merup M, et al. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer. 2008;123(5):1025–33. doi:10.1002/ijc.23584.
Sanchez C, de Ceballos ML, del Pulgar T G, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001;61(15):5784–9.
Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 2008;68(15):6468–76. doi:10.1158/0008-5472.can-08-0896.
Larrinaga G, Sanz B, Blanco L, Perez I, Candenas ML, Pinto FM, et al. Cannabinoid CB1 receptor is expressed in chromophobe renal cell carcinoma and renal oncocytoma. Clin Biochem. 2013;46(7–8):638–41. doi:10.1016/j.clinbiochem.2012.12.023.
Larrinaga G, Sanz B, Perez I, Blanco L, Candenas ML, Pinto FM, et al. Cannabinoid CB(1) receptor is downregulated in clear cell renal cell carcinoma. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2010;58(12):1129–34. doi:10.1369/jhc.2010.957126.
Williams DJ, Cohen C, To TV, Page AJ, Lawson D, Sussman ZM, et al. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. Hum Pathol. 2009;40(8):1176–81. doi:10.1016/j.humpath.2009.01.003.
McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. Journal of immunology (Baltimore, Md : 1950). 2005;174(6):3281–9.
Carpi S, Fogli S, Romanini A, Pellegrino M, Adinolfi B, Podesta A, et al. AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells. Anti-Cancer Drugs. 2015;26(7):754–62. doi:10.1097/cad.0000000000000246.
Fiori JL, Sanghvi M, O’Connell MP, Krzysik-Walker SM, Moaddel R, Bernier M. The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor alpha protein. Br J Pharmacol. 2011;164(3):1026–40. doi:10.1111/j.1476-5381.2011.01384.x.
This work was supported by the National Natural Science Foundation of China (No. 81472378, No. 81272841, and No. 91129725) and the Shanghai Committee of Science and Technology (13ZR1425100). All these study sponsors have no roles in the study design, in the collection, analysis, and interpretation of data.
Conflicts of interest
This investigation was approved by the Ethics and Research Committees of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and was conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines.
Jianfeng Wang and Yunze Xu contributed equally to this work
About this article
Cite this article
Wang, J., Xu, Y., Zou, Y. et al. Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression. Tumor Biol. 37, 16237–16247 (2016). https://doi.org/10.1007/s13277-016-5447-6
- Renal cell carcinoma
- Cannabinoid receptor 1